


Biosketch

Longqin Hu, Ph.D. (胡龙勤)

**Professor of Medicinal Chemistry
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, NJ 08854
Tel: 732-445-5291
Fax: 732-445-6312
Email: LongHu@rutgers.edu**



Longqin Hu received his Bachelor degree in Pharmacy in 1984 and a Master's degree in Medicinal Chemistry in 1987 from the Second Military Medical University in Shanghai, China. From 1988 to 1993, he studied for his Ph.D. degree in Medicinal Chemistry at the University of Kansas under the direction of Professor Michael B. Doughty. His doctoral dissertation was on neuropeptide Y analogues as probes of a bioactive tertiary structure. After receiving his doctoral degree in Medicinal Chemistry, he worked as an NIH postdoctoral fellow with Professor Roberta F. Colman in Biochemistry at the University of Delaware. His postdoctoral research was focused on the affinity labeling and solution conformational studies of glutathione S-transferases. Dr. Hu started his academic career in 1996 as an Assistant Professor of Medicinal Chemistry at the University of Oklahoma College of Pharmacy. In 1999, he moved to Rutgers University, rose through the ranks, and is currently a Professor of Medicinal Chemistry in the Department of Pharmaceutical Chemistry, Ernest Mario School of Pharmacy. He has been a member of the Cancer Institute of New Jersey since 2001. His current research interests are in the general area of synthetic medicinal chemistry and bioorganic chemistry. Specifically, his laboratory is working on the synthesis and evaluation of anticancer prodrugs for the site-specific activation in tumor tissues, the design and synthesis of mechanism-based inhibitors of protein serine/threonine kinases, and the development of small molecule inhibitors that interfere with the protein-protein interactions between Eph receptors and ephrins and between Keap1 and Nrf2. His research has been funded by grants from the National Institutes of Health, the American Cancer Society, Department of Defense Medical Research Programs, the State of New Jersey Commission of Cancer Research, and Pardee Foundation.